Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
1.291
+0.021 (1.66%)
Mar 24, 2026, 1:22 PM EDT - Market open

Silexion Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
464--
Market Cap Growth
-61.57%61.50%---
Enterprise Value
0.281.875.8600
Last Close Price
1.291.9230.15--
PE Ratio
-0.210.08--
PB Ratio
1.532.31-0.93--
P/TBV Ratio
0.660.98-0.31--
P/FCF Ratio
--0.55-0.44--
P/OCF Ratio
--0.55-0.44--
EV/EBITDA Ratio
--0.16-0.47--
EV/EBIT Ratio
--0.16-0.47--
EV/FCF Ratio
--0.17-0.70--
Debt / Equity Ratio
0.710.71-0.830.020.02
Debt / EBITDA Ratio
-0.17-0.17-0.28-0.04-0.07
Debt / FCF Ratio
-0.19-0.19-0.41-0.04-0.08
Net Debt / Equity Ratio
-1.52-1.52-0.580.290.80
Net Debt / EBITDA Ratio
0.340.34-0.180.952.23
Net Debt / FCF Ratio
0.370.37-0.270.972.52
Quick Ratio
2.172.170.342.095.44
Current Ratio
2.412.410.642.275.49
Return on Equity (ROE)
1718.90%1718.90%3343.93%-96.67%-46.09%
Return on Assets (ROA)
-230.90%-230.90%-309.86%-64.58%-41.65%
Return on Invested Capital (ROIC)
1143.48%1143.48%1319.90%438.59%420.19%
Return on Capital Employed (ROCE)
-612.69%-612.69%-1047.58%-86.82%-49.98%
Earnings Yield
-281.60%466.67%1309.92%--
FCF Yield
-255.98%-180.37%-226.46%--
Buyback Yield / Dilution
-311.17%-311.17%-144.03%--
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q